Oli, Mishra, Srivastava, Mishra, and Brighten: Study of incidence of heart failure in COPD exacerbation- A study in north India


Introduction

Chronic obstructive pulmonary disease is a major public health problem that has high prevalence and chronicity which affects around 329 million people worldwide and is the third leading cause of death.1 In India it is estimated that 30 million people are suffering from COPD and has the highest mortality in the world, data suggests that about 556,000, i.e. (>20%) of total 2,748,000 die in India annually.2, 3 The major risk factor for COPD is smoking. It is responsible for 40% to 70% of COPD cases. Globally, 84% of smokers live in developing and transitional economy countries.4 COPD along with accompanying cardiac disease are common due to shared risk factors like aging, cigarette smoke, inactivity, low-grade pulmonary and systemic inflammation.

HF is a clinical syndrome with typical symptoms caused by a structural and/or functional cardiac abnormality and resulting in reduced cardiac output and/or elevated intracardiac pressures.5 HF is defined according to left ventricular ejection fraction (EF): HF with preserved EF (HFpEF) (i.e., EF ≥ 50%) or HF with reduced EF (HFrEF) (i.e., EF < 40%).

COPD is frequently accountable for delayed diagnosis of HF and vice versabecause they both have similar clinical feature such as dyspnea and poor exercise tolerance.

Aim of Study

To study the incidence of heart failure in patients with COPD exacerbation.

Materials and Methods

Our study is a cross-sectional comparative study. In the group 1 patient with exacerbation of COPD with respiratory failure as per Gold Initiative for Obstructive Lung Disease guidelines.1 The study was conducted in Sir Sundarlal hospital, Banaras Hindu University (BHU), Varanasi from August 2018 to July 2020. Approval of the ethical committee was obtained in July 2018.

Inclusion criteria

Adult aged >40 years with diagnosis of COPD as per GOLD guidelines,

  1. COPD patient on Indian population

  2. Respiratory rate (RR) > 30 breaths per min or <12/min

  3. Signs of increased work of breathing or paradoxical respiration

  4. Partial pressure of (PC02) >45 mmHg

  5. Arterial pH <7.35.

Exclusion criteria

  1. Patient not giving consent.

  2. Unconscious patient.

  3. Need for endotracheal intubation on admission to protect the airways or to manage respiratory secretions.

  4. Inability to properly fit the facemask due to skeletal deformity.

In total 142 patients were enrolled for this study. 81 patients in respiratory failure group and 61 patients in non-respiratory failure group. The study was planned to include 100 patients in each group however due to pandemic and time limit we had to conclude our study. During hospital admission all patients were treated with standard protocol including oxygen support, oral or intravenous antibiotics and oral or intravenous steroids as recommended by treating physician. Non-invasive ventilation and Invasive ventilation were done whenever mandated and possible. Patients with NIV were shifted to High dependency Unit (HDU). Patients with heart failure were treated as per standard guidelines. Patients were ventilated with Phillips Respironics using oro-nasal mask. The ventilator settings that were used are: BiPAP, S/T, AVAPS mode with an IPAP min/max 16/30 cm H2O,EPAP 6-8 cm H2O, respiratory backup rate was 16/min, target volume of 5-7 ml/kg. Adjustment of these parameters were done on the basis of ABG analysis, oximetry, patients tolerance, patient ventilator synchrony as per our protocol.

NIV was initially administered as long as necessary to maintain pH ≥ 7.35, followed by gradual decrease over time. Initial ABG was done immediately after admission in Chest Ward following standard guidelines. Repeat ABG was done and clinical parameters were re-assessed as per our hospital protocol. BNP levels were measured at the time of admission. A complete workup including 2D-Echo was done.

2D-echocardiography was done by a multi-frequency probe with a range of 2-4.3 MHz both 2D and M-mode studies were done. Echo was done to review the pericardium, valvular anatomy and function, both sided chamber size and cardiac function.

Measures of right ventricular functions

Right ventricle dimension was measured by M-mode echocardiography, and right ventricular dilation (Cor-pulmonale) was present when it exceeded the normal range of 0.9-2.6 cm. Right ventricle contractility was also noted, and right ventricular systolic dysfunction was said to be present when it was hypokinetic.

Measures of left ventricular functions:

E/A = diastolic filling of left ventricles usually classified initially on the basis of the peak mitral flow velocity of the early rapid filling wave (E), peak velocity of the late filling wave caused by atrial contraction (A). In normal subjects, LV elastic recoil is vigorous because of normal myocardial relaxation, therefore, more filling is completed during early diastolic, so LVDD is said to be present when E/A is <1.3 (age group 45-49 years), <1.2 (age group 50-59 years), <1.0 (age group 60-69 years), and <0.8 (age group ≥70 years).6

Data analysis was done using version of SPSS software. Patient characteristics were described using means and SD for continuous variables and frequency with percentages for categorical variables.

Results

Our study involved 142 clinically and spirometrically proven COPD patients.81 Patients were in respiratory failure group.61 patients were in the non-respiratory failure group.

Table 1

Patient characteristics among respiratory failure and non-respiratory failure group

Variables

Respiratory failure group(n=81) (Group-1)

Non-respiratory failure group (n=61) (Group 2)

p-value

t-value

Age

64.02±9.97

62.87±7.60

0.45

0.75

Gender

Males

39(48.1%)

35(57.4%)

0.28

1.19

Females

42(51.9%)

26(42.6%)

Heart failure

Present

41(50.6%)

6(9.8%)

Absent

40(49.4%)

55(90.2%)

BNP

656.32±623.16

159.91±303.04

<0.001

-5.72

In our study the mean age of the study group was 64.02±9.97 in the respiratory failure group and 62.87±7.60 in the non-failure group. There was almost equal distribution based on gender.

Figure 1

Incidence of heart failure among the study groups

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/d89c8cdd-1ce7-4d44-9004-75fdcd57019f/image/d8bbb311-6822-4b8b-8d68-c2adfdcb65c8-uimage.png

Table 2

Percentage distribution of heart failure

Heart failure

Respiratory failure

Non-respiratory failure

Rt sided heart failure

82.92%(n=34)

33.33%(n=2)

Lt sided heart failure

17.07%(n=7)

66.66%(n=4)

Table 3

Incidence of shared risk factor for both COPD and heart failure

Risk Factor

Respiratory failure group(n=81) (Group-1)

Non-respiratory failure group (n=61) (Group-2)

Number (n)

Percentage (%)

Number(n)

Percentage

Smoker

Current

12

14.81%

10

16.39%

Former

64

79.01%

30

49.18%

Never smoked

5

6.17%

21

34.42%

Biomass exposure

5

6.17%

21

34.42%

H/O exacerbation/admission within 1 year

81

100%

20

32.78%

Hypertension

10

12.34%

12

19.67%

Diabetes Mellitus

22

27.16%

16

26.22%

Coronary artery Disease

8

9.87%

6

9.83%

Racial origin

Indian population

The incidence of heart failure was present 50.6%(n=41) and 9.8%(n=6) respectively in the respiratory failure group and non-respiratory failure group. In group 1 the incidence of Cor-pulmonale was present is 82.92%(n=34) whereas in the non-failure group the incidence of Left ventricular dysfuction 66.66%(n=4) was more common.

Our study shows that overall incidence of heart failure was more common in COPD exacerbation with respiratory failure compared to non-failure group.

Discussion

COPD is a multifactorial disease. COPD affects pulmonary blood vessels, right ventricle, as well as left ventricle leading to the development of pulmonary hypertension (PH), cor-pulmonale (COR-P), right ventricular dysfunction, and left ventricular dysfunction. Ischemic heart disease is one of the main causes of mortality in COPD.7

In our study the overall incidence of heart failure in COPD exacerbation was 33.09%(n=47). However individually in between groups respiratory failure group and non-failure group was 50.6%(n=41), 9.8%(n=6) respectively.

In our study in RF group cor-pulmonale was present is 82.92%(n=34) whereas in the NRF group the incidence of Left ventricular dysfuction was more common. Hence our study shows that with increased severity of disease the right sided heart failure was more prevalent. Our findings are consistent with the findings by Vizza CD et al.8 in which they concluded that prevalence of right ventricular dysfunction is high in patients with end-stage pulmonary disease, but the prevalence of left ventricular dysfunction is relatively low. Left ventricular dysfunction appears to be related to right ventricular dysfunction, perhaps through ventricular interdependence.

Another study by Kawut SM et al.9 in hospitalized patients with moderate/severe COPD, 48% demonstrated abnormality of RV structure/function, with RV enlargement being the most common (29.9%). Our findings are consistent with increased right heart failure in severe exacerbation with RF. RV failure confers a poor prognosis in COPD.10, 11

In our study the incidence of HTN, DM and CAD was 12.34%, 27.16%, 9.87% respectively in the respiratory failure group whereas in the non respiratory failure group the incidence was 19.67%, 26.22% and 9.83% respectively. In a study conducted in Spain by Almagro et al.12 (2010) they found that 55% of the patients had hypertension, 26% diabetes mellitus, 27% chronic heart failure, and 17% ischemic heart disease. Female COPD patients had a lower prevalence of ischemic heart disease. However in our study there was no gender disparity. Another study done by Baty et al.,13 (2013) they found that prevalence of HF, IHD, Arrythmias was 11%,25% and 13% respectively they also concluded that co-morbities were associated with worst outcome.

In our study in the respiratory failure group there was h/o previous hospitalization for exacerbation within past year in almost all patients whereas in the non-respiratory failure group only 32.78% patients had history of hospitalization. According to Garcia-Gutierrez et al.,14 predictors of previous hospitalization were severity of current COPD exacerbation, response to previous treatment, and expected adherence to treatment.

Limitations of Study

The limitations of our study was a small sample size and also we were not able to perform right heart catheterization or Transesophageal echocardiography. However the results are encouraging.

Source of Funding

None.

Conflict of Interest

None.

References

1 

2 

AD Lopez K Shibuya C Rao CD Mathers AL Hansell LS Held Chronic obstructive pulmonary disease: Current burden and future projectionsEur Respir J200627397412

3 

S Salvi A Agrawal India needs a national COPD prevention and control programmeJ Assoc Physicians India20126057

4 

GG Woldeamanuel AB Mingude TG Geta Prevalence of chronic obstructive pulmonary disease (COPD) and its associated factors among adults in Abeshge District, Ethiopia: a cross sectional studyBMC Pulm Med201919118110.1186/s12890-019-0946-z

5 

P Ponikowski AA Voors SD Anker H Bueno ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESCEur Heart J20163721292200

6 

P Libby RO Bonow DP Zipes DL Mann Braunwald′s Heart Disease8th editionSaundersPhiladelphia2008251

7 

NR Anthonisen MA Skeans RA Wise J Manfreda RE Kanner Connett JE; Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: A randomized clinical trialAnn Intern Med20051422339

8 

CD Vizza JP Lynch LL Ochoa G Richardson EP Trulock Right and Left Ventricular Dysfunction in Patients With Severe Pulmonary DiseaseChest199811335768310.1378/chest.113.3.576

9 

SM Kawut HD Poor MA Parikh K Hueper BM Smith DA Bluemke Cor Pulmonale Parvus in Chronic Obstructive Pulmonary Disease and EmphysemaJ Am Coll Cardiol201464192000910.1016/j.jacc.2014.07.991

10 

G Dournes F Laurent F Coste C Dromer E Blanchard F Picard Computed Tomographic Measurement of Airway Remodeling and Emphysema in Advanced Chronic Obstructive Pulmonary Disease. Correlation with Pulmonary HypertensionAm J Respir Crit Care Med20151911637010.1164/rccm.201408-1423oc

11 

P Solidoro F Patrucco R Bonato M Boffini D Libertucci D Ricci Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease and Pulmonary Fibrosis: Prevalence and Hemodynamic Differences in Lung Transplant Recipients at Transplant Center's Referral TimeTransplant Proc20154772161510.1016/j.transproceed.2015.01.031

12 

P Almagro FL García FJ Cabrera L Montero D Morchón J Díez Comorbidity and gender-related differences in patients hospitalized for COPD. The ECCO studyRespir Med20101042253910.1016/j.rmed.2009.09.019

13 

F Baty PM Putora B Isenring T Blum M Brutsche Comorbidities and Burden of COPD: A Population Based Case-Control StudyPLoS ONE201385e6328510.1371/journal.pone.0063285

14 

S Garcia-Gutierrez JM Quintana A Bilbao A Unzurrunzaga C Esteban M Baré Validity of criteria for hospital admission in exacerbations of COPDInt J Clin Pract2014687820910.1111/ijcp.12397



jats-html.xsl

© This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


  • Article highlights
  • Article tables
  • Article images

Article History

Received : 15-05-2021

Accepted : 24-05-2021

Available online : 27-07-2021


View Article

PDF File   Full Text Article


Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/10.18231/j.jchm.2021.019


Article Metrics






Article Access statistics

Viewed: 155

PDF Downloaded: 54



Wiki in hindi